Autolus Therapeutics (NASDAQ:AUTL) Earns “Buy” Rating from Needham & Company LLC

Autolus Therapeutics (NASDAQ:AUTL)‘s stock had its “buy” rating reaffirmed by Needham & Company LLC in a report released on Friday,Benzinga reports. They presently have a $10.00 target price on the stock.

A number of other equities research analysts have also recently commented on AUTL. William Blair reissued an “outperform” rating on shares of Autolus Therapeutics in a research note on Wednesday, September 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Autolus Therapeutics in a report on Wednesday, October 8th. Finally, Wall Street Zen downgraded shares of Autolus Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Saturday, November 15th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $8.33.

Autolus Therapeutics Stock Up 1.3%

Shares of AUTL stock opened at $1.61 on Friday. The firm has a 50 day moving average of $1.49 and a 200-day moving average of $1.81. The company has a market cap of $428.49 million, a price-to-earnings ratio of -1.94 and a beta of 2.01. Autolus Therapeutics has a 52 week low of $1.11 and a 52 week high of $2.80.

Autolus Therapeutics (NASDAQ:AUTL) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.07). Autolus Therapeutics had a negative return on equity of 63.76% and a negative net margin of 439.69%.The company had revenue of $21.19 million for the quarter, compared to the consensus estimate of $21.08 million. Analysts anticipate that Autolus Therapeutics will post -0.94 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the company. R Squared Ltd boosted its holdings in Autolus Therapeutics by 40.1% during the third quarter. R Squared Ltd now owns 30,476 shares of the company’s stock worth $50,000 after purchasing an additional 8,730 shares during the last quarter. Tema Etfs LLC lifted its position in shares of Autolus Therapeutics by 9.0% during the 2nd quarter. Tema Etfs LLC now owns 120,388 shares of the company’s stock worth $274,000 after buying an additional 9,960 shares in the last quarter. The Manufacturers Life Insurance Company boosted its stake in shares of Autolus Therapeutics by 41.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 38,419 shares of the company’s stock worth $88,000 after buying an additional 11,289 shares during the last quarter. Invesco Ltd. grew its holdings in shares of Autolus Therapeutics by 53.3% in the first quarter. Invesco Ltd. now owns 32,738 shares of the company’s stock valued at $51,000 after acquiring an additional 11,381 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC grew its holdings in shares of Autolus Therapeutics by 63.5% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 30,432 shares of the company’s stock valued at $69,000 after acquiring an additional 11,821 shares in the last quarter. 72.83% of the stock is owned by institutional investors.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.